<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454869</url>
  </required_header>
  <id_info>
    <org_study_id>89-04-129-12415</org_study_id>
    <nct_id>NCT01454869</nct_id>
  </id_info>
  <brief_title>The Effect of Heparin on Inhalation Injury</brief_title>
  <official_title>Efficacy of Heparin Nebulization on Lung Injury Score in Inhalation Burn Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized clinical trial about the efficacy of heparin nebulization on
      lung injury score in inhalation burn injury in Mothary burn hospital. This study would
      consist of 170 burn patients with documented inhalation injury in 2 arms (control group and
      study group). Allocation ratio is1:1. Masking was not possible. The patients' primary outcome
      will be assessed for Lung Injury Scale and the patients' secondary outcome will be assessed
      for mortality, Coagulation tests (PT, PTT), ICU and hospital stay and duration of mechanical
      ventilation support. Duration of this study is about 32 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study would consist of 170 burn patients with documented smoke inhalation injury who
      will be randomized to receive either standard care alone (control group) or standard care
      plus heparin nebulization in combination with intravenously administrated fresh frozen plasma
      (study group). Standard care treatment consist of: chest physiotherapy ,early ambulation,
      airway suctioning, bronchial hygiene therapy , salbutamol nebulization (100-200
      µgQ4h)/N-acetyl cysteine 20% nebulization (3cc Q4h) and if needed mechanical ventilation
      support. Study care treatment consist of: Standard care + Heparin nebulized
      administration(5000U every 4 hours for 7 days) and fresh frozen plasma intravenously
      administration (10 cc/Kg daily for 7 days) The patients' primary outcome will be assessed for
      Lung Injury Scale (LIS) every day by using fallowing parameters: (1) chest X-ray evaluated
      for alveolar consolidation (2) ratio of the partial pressure of oxygen in arterial blood to
      the inspiratory fraction of oxygen (3) PEEP level if ventilated (4) respiratory compliance if
      known Parameter Finding Value Rx.Torax no alveolar consolidation 0 alveolar consolidation de
      1 quadrant 1 alveolar consolidation de 2 quadrant 2 alveolar consolidation de 3 quadrant 3
      alveolar consolidation de 4 quadrant 4 Hypoxemia PaO2/FIO2 &gt; 300 0 PaO2/FIO2 225 - 299 1
      PaO2/FIO2 175 - 224 2 PaO2/FIO2 100 - 174 3 PaO2/FIO2 &lt; 100 4 PEEP PEEP &lt;= 5 cm H2O 0 PEEP 6
      - 8 cm H2O 1 PEEP 9 - 11 cm H2O 2 PEEP 12 - 14 cm H2O 3 PEEP &gt;= 15 cm H2O 4 Compliance &gt;= 80
      mL/cm H2O 0 compliance 60 - 79 mL/cm H2O 1 compliance 40 - 59 mL/cm H2O 2 compliance 20 - 39
      mL/cm H2O 3 compliance &lt;= 19 mL/cm H2O 4 2 The patients' secondary outcome will be assessed
      for mortality(for 28 days post injury), Coagulation tests(PT,PTT) (for 7 days post
      injury),ICU and hospital stay(for 7 days post injury) and duration of mechanical ventilation
      support(for 7 days post injury). In each group 85 Patients will be selected by simple
      randomization. Allocation ratio is1:1. Blinding of this study was not possible.

      PEEP: positive end expiratory pressure- PaO2: partial pressure of oxygen in arterial blood-
      FIO2: inspiratory fraction of oxygen PT: prothrombin time- PTT: partial thrombin time- ICU:
      intensive care unite- Rx: X-Ray
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to insufficient funds
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung Injury Score</measure>
    <time_frame>Daily untill 7 days post injury</time_frame>
    <description>(1) chest X-ray evaluated for alveolar consolidation (2) ratio of the partial pressure of oxygen in arterial blood to the inspiratory fraction of oxygen (3) PEEP level if ventilated (4) respiratory compliance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days post injury</time_frame>
    <description>Physical exam &amp; EKG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pt/ptt</measure>
    <time_frame>Up to 7 days post injury</time_frame>
    <description>Daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>7 days post injury</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>7 days post injury</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heparin</condition>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nac + salotamul</description>
  </arm_group>
  <arm_group>
    <arm_group_label>heparin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>heparin group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.</description>
    <arm_group_label>Standard care</arm_group_label>
    <other_name>routin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).</description>
    <arm_group_label>heparin group</arm_group_label>
    <other_name>new</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Burn patients admitted to Motahary burn center with documented inhalation injury (as
             defined by clinical or bronchoscopic evaluation)

        Exclusion Criteria:

          -  Non-survivable burn patients;

          -  history of coagulation disease;

          -  chronic obstructive pulmonary disease(COPD);

          -  pneumonia diagnosed at admission;

          -  inability to confirm definitive diagnosis of inhalation injury and co poisoning or
             Cyanide hydrogen intoxication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seyed H Salehi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Burn research of Tehran university of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shahid Mothary Burn Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://research.tums.ac.ir</url>
    <description>Tehran university of medical sciences (burncenter_89@yahoo. com)</description>
  </link>
  <reference>
    <citation>Maybauer MO, Rehberg S, Traber DL, Herndon DN, Maybauer DM. [Pathophysiology of acute lung injury in severe burn and smoke inhalation injury]. Anaesthesist. 2009 Aug;58(8):805-12. doi: 10.1007/s00101-009-1560-x. Review. German.</citation>
    <PMID>19517070</PMID>
  </reference>
  <reference>
    <citation>Brown M, Desai M, Traber LD, Herndon DN, Traber DL. Dimethylsulfoxide with heparin in the treatment of smoke inhalation injury. J Burn Care Rehabil. 1988 Jan-Feb;9(1):22-5.</citation>
    <PMID>3356738</PMID>
  </reference>
  <reference>
    <citation>Enkhbaatar P, Esechie A, Wang J, Cox RA, Nakano Y, Hamahata A, Lange M, Traber LD, Prough DS, Herndon DN, Traber DL. Combined anticoagulants ameliorate acute lung injury in sheep after burn and smoke inhalation. Clin Sci (Lond). 2008 Feb;114(4):321-9.</citation>
    <PMID>17927568</PMID>
  </reference>
  <reference>
    <citation>Desai MH, Mlcak R, Richardson J, Nichols R, Herndon DN. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine [correction of acetylcystine] therapy. J Burn Care Rehabil. 1998 May-Jun;19(3):210-2. Erratum in: J Burn Care Rehabil 1999 Jan-Feb;20(1 Pt 1):49.</citation>
    <PMID>9622463</PMID>
  </reference>
  <reference>
    <citation>Cancio LC. Airway management and smoke inhalation injury in the burn patient. Clin Plast Surg. 2009 Oct;36(4):555-67. doi: 10.1016/j.cps.2009.05.013. Review.</citation>
    <PMID>19793551</PMID>
  </reference>
  <reference>
    <citation>Toon MH, Maybauer MO, Greenwood JE, Maybauer DM, Fraser JF. Management of acute smoke inhalation injury. Crit Care Resusc. 2010 Mar;12(1):53-61. Review.</citation>
    <PMID>20196715</PMID>
  </reference>
  <reference>
    <citation>Muller MJ, Pegg SP, Rule MR. Determinants of death following burn injury. Br J Surg. 2001 Apr;88(4):583-7.</citation>
    <PMID>11298629</PMID>
  </reference>
  <reference>
    <citation>Tredget EE, Shankowsky HA, Taerum TV, Moysa GL, Alton JD. The role of inhalation injury in burn trauma. A Canadian experience. Ann Surg. 1990 Dec;212(6):720-7.</citation>
    <PMID>2256764</PMID>
  </reference>
  <reference>
    <citation>Shirani KZ, Pruitt BA Jr, Mason AD Jr. The influence of inhalation injury and pneumonia on burn mortality. Ann Surg. 1987 Jan;205(1):82-7.</citation>
    <PMID>3800465</PMID>
  </reference>
  <reference>
    <citation>Darling GE, Keresteci MA, Ibañez D, Pugash RA, Peters WJ, Neligan PC. Pulmonary complications in inhalation injuries with associated cutaneous burn. J Trauma. 1996 Jan;40(1):83-9.</citation>
    <PMID>8577005</PMID>
  </reference>
  <reference>
    <citation>Murakami K, Enkhbaatar P, Shimoda K, Mizutani A, Cox RA, Schmalstieg FC, Jodoin JM, Hawkins HK, Traber LD, Traber DL. High-dose heparin fails to improve acute lung injury following smoke inhalation in sheep. Clin Sci (Lond). 2003 Apr;104(4):349-56.</citation>
    <PMID>12653676</PMID>
  </reference>
  <reference>
    <citation>Jänne O, Kontula K, Vihko R. Review article: mechanism of action of female sex steroids. Acta Obstet Gynecol Scand Suppl. 1976;51:29-45.</citation>
    <PMID>180744</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <last_update_submitted>December 14, 2012</last_update_submitted>
  <last_update_submitted_qc>December 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heparin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

